Tianyan Pharmaceuticals Announces Data on Multiple Highly Differentiated, First-in-Class or Best Potential Preclinical Antibody Candidates at the 2022 American Cancer Society Annual Meeting

Suzhou, China and San Diego , U.

"The preclinical data presented in this poster are encouraging and show that Tianyan's differentiated preclinical antibody candidates have first-in-class or best-in-class potential to elicit safe, potent and durable immune responses

The four poster presentations are summarized as follows:

ADG206, a tailored anti-CD137 agonistic POWERbody® powerful antibody: Improves efficacy and safety of anti-CD137 monotherapy and combination cancer immunotherapy through robust cross-linking and tumor site-selective activation (#2868)

• This IgG1 Fc-optimized anti-CD137-masked POWERbody™ potent antibody combines activation under tumor microenvironmental conditions with high agonistic activity resulting from enhanced FcgR-mediated cross-linking, enhancing the potential efficacy of monotherapy and combination therapy
  
  
  • The difference of this anti-CD47 IgG1 subtype-masked SAFEbody™ safe antibody lies in its strong antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), which can fully release anti-CD47 Therapeutic potential of the therapy in hematological and solid tumor indications
    
    
    • This original HER2×CD3 POWERbody™ powerful antibody adopts a double-arm masking design.
      
      
      • CD28 bispecific POWERbody® potent antibody TCEs have great potential to be combined with CD3 bispecific POWERbody® potent antibody TCEs and/or checkpoint inhibitors to create safe and durable T cell-mediated synergistic immunotherapy regimens
        
        

        Tianyan Pharmaceutical (Nasdaq: ADAG) is a platform-driven clinical product development stage biopharmaceutical company with independent platform outputs.

        
        

        For more information, please visit:https://investor.

        
        

        SAFEbody ^® is a registered trademark of Tianyan in the United States, China, Australia, Japan, Singapore and the European Union

        
        

        Safe Harbor Statement

        This press release contains forward-looking statements, including statements regarding preclinical studies of ADG138, ADG206, ADG153G-1 and bispecific potent antibodies targeting CD28, the potential impact of the results of the preclinical studies of these antibodies, and the advancement of Tianyan Pharmaceuticals and anticipated clinical development, regulatory milestones, and commercialization of Tianyan's pipeline product candidates